Very Late Stent Thrombosis and Late Target Lesion Revascularization after Sirolimus-Eluting Stent Implantation: Five-Year Outcome of the j-Cypher Registry

Circulation

Volumn 125, Issue 4, 2012, Pages 584-591

  Kimura, Takeshi ^a   Morimoto, Takeshi ^a   Nakagawa, Yoshihisa ^b   Kawai, Kazuya ^c   Miyazaki, Shunichi ^d   Muramatsu, Toshiya ^e   Shiode, Nobuo ^f   Namura, Masanobu ^g   Sone, Takahito ^h   Oshima, Shigeru ⁱ   Nishikawa, Hideo ^j   Hiasa, Yoshikazu ^k   Hayashi, Yasuhiko ^l   Nobuyoshi, Masakiyo ^m   Mitudo, Kazuaki ⁿ  

^a KYOTO UNIVERSITY   (Japan)

^b TENRI HOSPITAL   (Japan)

^c Chikamori Hospital   (Japan)

^d NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^e Kawasaki Social Insurance Hospital   (Japan)

^f MATSUE RED CROSS HOSPITAL   (Japan)

^g KANAZAWA CARDIOVASCULAR HOSPITAL   (Japan)

^h OGAKI MUNICIPAL HOSPITAL   (Japan)

ⁱ GUNMA PREFECTURAL CARDIOVASCULAR CENTER   (Japan)

^j Mie Heart Center   (Japan)

^k TOKUSHIMA RED CROSS HOSPITAL   (Japan)

^l TSUCHIYA GENERAL HOSPITAL   (Japan)

^m KOKURA MEMORIAL HOSPITAL   (Japan)

ⁿ KURASHIKI CENTRAL HOSPITAL   (Japan)

more..

Author keywords

coronary artery disease; prognosis; restenosis; stents; thrombosis

Indexed keywords

RAPAMYCIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; DIABETES MELLITUS; DRUG ELUTING STENT; FEMALE; HEART MUSCLE REVASCULARIZATION; HEMODIALYSIS; HUMAN; INCIDENCE; KIDNEY FAILURE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REGISTER; RISK FACTOR; SMOKING; STENT THROMBOSIS; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DEATH, SUDDEN, CARDIAC; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; REGISTRIES; RISK FACTORS; SIROLIMUS; TIME FACTORS;

EID: 84857053550     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.046599     Document Type: Article

References (16)

1. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai K, Jensen LO, Park SJ, Perry R, Racz M, Saia F, Tu JV, Waksman R, Lansky AJ, Mehran R, Stone GW. Safety and efficacy of drug-eluting and bare metal stents: comparative meta-analysis of randomized trials and observational studies. Circulation. 2009;119: 3198-3206.
2. Bar SS, Leon MB, Stone GW, Mehran R, Moses JW, Brar SK, Dangas G. Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis. J Am Coll Cardiol. 2009;53:1677-1689.
3. Yamaji K, Kimura T, Nakagawa Y, Inoue K, Soga Y, Arita T, Shirai S, Ando K, Kondo K, Sakai K, Goya M, Iwabuchi M, Yokoi H, Nosaka H, Nobuyoshi M. Very long-term (15-20 years) clinical and angiographic outcome after coronary bare-metal stent implantation. Circ Cardiovasc Interv. 2010;3:468-475.
4. Wenaweser P, Daemen J, Zwahlen M, van Domburg R, Juni P, Vaina S, Hellige G, Tuchida K, Morger C, Boersma E, Kukreja N, Meier B, Serruys PW, Windecker S. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. J Am Coll Cardiol. 2008;52: 1134-1140.
5. Nakagawa Y, Kimura T, Morimoto T, Nomura M, Saku K, Haruta S, Muramatsu T, Nobuyoshi M, Kadota K, Fujita H, Tatami R, Shiode N, Nishikawa H, Shibata Y, Miyazaki S, Murata Y, Honda T, Kawasaki T, Doi O, Hiasa Y, Hayashi Y, Matsuzaki M, Mitudo K. Incidence and risk factors of late target lesion revascularization after sirolimus-eluting stent implantation (3-year follow-up of the j-Cypher registry). Am J Cardiol. 2010;106:329-336.
6. Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, Nishikawa H, Hiasa Y, Muramatsu T, Meguro T, Inoue N, Honda H, Hayashi Y, Miyazaki S, Oshima S, Honda T, Shiode N, Namura M, Sone T, Nobuyoshi M, Kita T, Mitudo K. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation. 2009; 119:987-995.
7. Serruys PW, Ong AT, van Herwerden LA, Sousa JE, Jatene A, Bonnier JJ, Schönberger JP, Buller N, Bonser R, Disco C, Backx B, Hugenholtz PG, Firth BG, Unger F. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol. 2005;46:575-581. (Pubitemid 41132680)
8. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356:1020-1029. (Pubitemid 46376802)
9. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statist Med. 1999;18:695-706. (Pubitemid 29126745)
10. Caixeta A, Leon MB, Lansky AJ, Nikolsky E, Aoki J, Moses JW, Schofer J, Morice MC, Schampaert E, Kirtane AJ, Popma JJ, Parise H, Fahy M, Mehran R. 5-Year clinical outcomes after sirolimus-eluting stent implantation: insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. J Am Coll Cardiol. 2009;54:894-902.
11. Ellis SG, Stone GW, Cox DA, Hermiller J, O'Shaughnessy C, Mann T, Turco M, Caputo R, Bergin PJ, Bowman TS, Baim D. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS® clinical trial (TAXUS®-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). J Am Coll Cardiol Cariovasc Interv. 2009;2:1248-1259.
12. Mauri L, Massaro JM, Jiang S, Jiang S, Meredith I, Wijns W, Fajader J, Kandzari DE, Leon MB, Cutrip DE, Thompson KP. Long-term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents. J Am Coll Cardiol Cardiovasc Interv. 2010;3:1240-1249.
13. Vink MA, Dirksen MT, Suttorp MJ, Tijssen JGP, van Etten J, Patterson MS, Slagboom T, Kiemeneij F, Laarman GJ. 5 Year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial. J Am Coll Cardiol Cardiovasc Interv. 2011;4:24-29.
14. Kimura T, Morimoto T, Kozuma K, Honda Y, Kume T, Aizawa T, Mitsudo K, Miyazaki S, Yamaguchi T, Hiyoshi E, Nishimura E, Isshiki T. Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART). Circulation. 2010;122:52-61.
15. Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, Han KH, Park SW, Yun SC, Lee SG, Rha SW, Seong IW, Jeong MH, Hur SH, Lee NH, Yoon J, Yang JY, Lee BK, Choi YJ, Chung WS, Lim DS, Cheong SS, Kim KS, Chae JK, Nah DY, Jeon DS, Seung KB, Jang JS, Park HS, Lee K. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med. 2010;362:1374-1382.
16. Ikari Y, Kotani J, Kozuma K, Kyo E, Nakamura M, Yokoi H. Assessment of sirolimus-eluting coronary stent implantation with aspirin and low dose ticlopidine administration: one year result from CYPHER Stent Japan Post-Marketing Surveillance Registry (J-PMS). Circ J. 2009;73:1038-1044.